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Abstract
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Novel 6-methyluracil derivatives with
ω-(substituted benzylethylamino)alkyl chains at the nitrogen atoms of the pyrimidine ring were
designed and synthesized. The numbers of methylene groups in the alkyl chains were varied
along with  the electron-withdrawing substituents  on the benzyl  rings.  The compounds are
mixed-type  reversible  inhibitors  of  cholinesterases,  and  some  of  them  show  remarkable
selectivity for human acetylcholinesterase (hAChE), with inhibitory potency in the nanomolar
range,  more than 10 000-fold  higher  than that  for  human butyrylcholinesterase (hBuChE).
Molecular modeling studies indicate that these compounds are bifunctional AChE inhibitors,
spanning the enzyme active site gorge and binding to its peripheral anionic site (PAS). In vivo
experiments show that the 6-methyluracil  derivatives are able to penetrate the blood-brain
barrier (BBB), inhibiting brain-tissue AChE. The most potent AChE inhibitor,  3 d (1,3-bis[5--
o-nitrobenzylethylamino)pentyl]-6-methyluracil),  was  found  to  improve  working  memory  in
scopolamine and transgenic APP/PS1 murine models of Alzheimer's disease, and to significantly
decrease the number and area of β-amyloid peptide plaques in the brain. Head-AChE relief! In
our  efforts  to  identify  compounds  to  treat  Alzheimer′s  disease,  we  found  that  1,3-bis[-
-(substituted  benzylethylamino)alkyl]-6-methyluracils  bind  to  the  active  site  gorge  and
peripheral anionic site of acetylcholinesterase (AChE). These compounds can cross the blood-
brain barrier, and decrease the number and area of β-amyloid plaques in the brain.
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